Dual Antiplatelet Treatment in the Coronary Artery Disease

References (3)

1. Meng Lee, Jeffrey L. Saver, Keun-Sik Hong, Neal M. Rao, Yi- LingWu, Bruce Ovbiagele. Antiplatelet Regimen for Pa - tients With Breakthrough StrokesWhile on Aspirin. Stroke 2018;49(3). Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, et al. (2016) Thelong-term therapy with low-dose aspirin did not reduce cardiovascular events in patients with type 2 dia- betes in primary prevention 10-year follow-up of a ran- domized controlled trial. Circul 2017;135(7):659-70.
2. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery dis- ease developed in collaboration with EACTS: theTask Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) [published online ahead of print August 26, 2017]. Eur Heart J doi: 10.1093/ eurheartj/ ehx419.https://acade- mic.oup.com/ eurheartj/ article-lookup/doi/10.1093/ eur- heartj/ ehx419. Developed in Collaboration with American Association for Thoracic Surgery, American Society of Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Published on March 29 th, 2016, available at: J Am Coll Cardiol http://content.onlinejacc.org/article.aspx?doi=10.1016 /j.jacc. 2016.03.513. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA boxed warning: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Con - sen sus Documents and the American Heart Associ ation. J Am Coll Cardiol 2010;56(4):321-41.
3. Qaderdan K, Ishak M, Heestermans AA. et al. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older - rationale and design of the POPular AGE study. Am Heart J 2015; 170(5): 981-5.e1. Sherwood MW, Wiviott SD, Peng SA, et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc 2014;3: e000849. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for